Clinical trials: Ovarian Cancer Recurrent
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
This phase II trial is studying the side effects and how well RO4929097 works in treating patients with recurrent and/or metastatic epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IV Fallopian Tube Cancer
- Trial name
- NCT01175343
- Testing
- Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis
- Where
- 12 sites in United States, Canada
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Fallopian Tube Cancer
Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer
The purpose of this study is to evaluate the safety and efficacy of niraparib in participants with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 3 or 4…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT03759600
- Testing
- Niraparib
- Where
- 33 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Takeda
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
This phase II trial studies how well rilotumumab works in treating patients with ovarian epithelial, fallopian tube, or primary peritoneal cancer that has failed to respond to other therapies (persistent) or has returned after a…
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01039207
- Testing
- Laboratory Biomarker Analysis, Rilotumumab
- Where
- 28 sites in United States
- Volunteers
- 31 people
- Sponsor
- Gynecologic Oncology Group
Recurrent Platinum Resistant Ovarian Cancer
Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer
This is an open label, single arm, multi-center study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in platinum-resistant relapsed high grade serous, high grade endometroid or clear cell…
- Trial name
- CONCERTO (NCT02889900)
- Testing
- cediranib and olaparib
- Where
- 25 sites in United States
- Volunteers
- 62 people
- Sponsor
- AstraZeneca
Fallopian Tube Clear Cell Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma
Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase II trial studies how well cabozantinib-s-malate works in treating patients with ovarian, fallopian tube, or primary peritoneal cavity cancer that has come back or is growing, spreading, or getting worse.
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT02315430
- Testing
- Cabozantinib S-malate, Laboratory Biomarker Analysis
- Where
- 410 sites in United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab
This phase II trial studies how well computed tomography perfusion imaging works in predicting outcomes in patients with ovarian, fallopian tube, or primary peritoneal cancer who are receiving bevacizumab.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT03412630
- Testing
- Computed Tomography Perfusion Imaging
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Carcinosarcoma, Ovarian
Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
This is a Phase 1 B feasibility trial with Galunsertib, a TGFβ inhibitor, in combination with carboplatin/paclitaxel in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary.
- Trial name
- NCT03206177
- Testing
- Galunisertib, Paclitaxel, Carboplatin
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Oklahoma
Fallopian Tube Cancer, Ovarian Cancer
Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma
RATIONALE: There is emerging data to suggest that the optimal use of angiogenesis inhibitors may be in combination with chemotherapy.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00653328
- Testing
- atrasentan hydrochloride, doxil
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Cancer
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
RATIONALE: Antithymocyte globulin, clofarabine, and rituximab may stop the patient's immune system from rejecting the donor's stem cells when they do not exactly match the patient's blood.
- Trial name
- NCT00617929
- Testing
- anti-thymocyte globulin, rituximab, clofarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Fallopian Tube Cancer, Ovarian Cancer
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00114166
- Testing
- topotecan hydrochloride
- Where
- 78 sites in United States
- Volunteers
- 81 people
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer
Gleevec Study for Patients With Ovarian Cancer
Primary Objectives: 1. To determine the efficacy of Gleevec in patients with recurrent platinum-resistant, taxane-resistant epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer whose tumor expresses…
- Trial name
- NCT00510653
- Testing
- Imatinib Mesylate
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- M.D. Anderson Cancer Center
Fallopian Tube Cancer, Ovarian Cancer
Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00522301
- Testing
- sorafenib tosylate, immunoenzyme technique, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Carcinoma, Fallopian Tube Carcinoma
(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
To evaluate progression-free survival with two chemotherapy regimens on platinum-resistant/refractory ovarian and peritoneal carcinoma
- Conditions
- Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma
- Trial name
- PGA (NCT01936974)
- Testing
- Gemcitabine, Bevacizumab, Carboplatin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Western Regional Medical Center
Cancer
Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer
RATIONALE: Massage therapy may help relieve symptoms associated with cancer. It is not yet known which type of massage therapy is more effective in treating the symptoms of patients with cancer.
- Trial name
- NCT00253708
- Testing
- management of therapy complications, massage therapy, pain therapy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Beth Israel Deaconess Medical Center
Ovarian Cancer
EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer
To learn if adding etigilimab to nivolumab therapy can help to control clear cell ovarian, fallopian tube, and primary peritoneal cancers that are resistant to platinum-based therapy
- Trial name
- NCT05715216
- Testing
- Nivolumab, Etigilimab
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer
The purpose of this study is to evaluate the effectiveness and tolerability of the combination of bevacizumab and Abraxane in the treatment of women with epithelial ovarian cancer or peritoneal cancer.
- Trial name
- NCT00407563
- Testing
- Bevacizumab, Abraxane
- Where
- 11 sites in United States
- Volunteers
- 48 people
- Sponsor
- Accelerated Community Oncology Research Network
Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
This randomized phase III trial studies carboplatin, paclitaxel and gemcitabine hydrochloride when given together with or without bevacizumab after surgery to see how well it works in treating patients with ovarian, epithelial…
- Conditions
- Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma
- Trial name
- NCT00565851
- Testing
- Bevacizumab, Carboplatin, Docetaxel
- Where
- 709 sites in United States, Japan and 1 more
- Volunteers
- 1,052 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer
Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)
This multi-centre, non-randomized open phase I/randomized phase II study will be conducted in 70 patients (10 in phase I, 60 in phase II) with platinum-refractory recurrent epithelial cancer of the ovary, fallopian tube or…
- Trial name
- ZACFAST (NCT00862836)
- Testing
- Vandetanib
- Where
- 5 sites in Germany
- Volunteers
- 15 people
- Sponsor
- Genzyme, a Sanofi Company
Ovarian Carcinoma, Primary Peritoneal Carcinoma
Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma
The purpose of this study is to determine if the combination of bevacizumab and pemetrexed have an effect on recurrent ovarian and primary peritoneal carcinoma by looking at progression and survival at 6 months.
- Trial name
- NCT00868192
- Testing
- Pemetrexed, Bevacizumab
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Washington University School of Medicine
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
The purpose of this study is to look at how patients respond to treatment with guadecitabine and pembrolizumab. The researchers will also be looking at the amount of time it takes for cancer to get worse when participants take…
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT02901899
- Testing
- Guadecitabine, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Northwestern University